SANA vs. APGE, CGON, KYMR, RXRX, VCEL, DNA, DNLI, TWST, BEAM, and FUSN
Should you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include Apogee Therapeutics (APGE), CG Oncology (CGON), Kymera Therapeutics (KYMR), Recursion Pharmaceuticals (RXRX), Vericel (VCEL), Ginkgo Bioworks (DNA), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Beam Therapeutics (BEAM), and Fusion Pharmaceuticals (FUSN). These companies are all part of the "biological products, except diagnostic" industry.
Apogee Therapeutics (NASDAQ:APGE) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.
Sana Biotechnology's return on equity of 0.00% beat Apogee Therapeutics' return on equity.
Apogee Therapeutics received 3 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 100.00% of users gave Apogee Therapeutics an outperform vote while only 50.00% of users gave Sana Biotechnology an outperform vote.
In the previous week, Sana Biotechnology had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 12 mentions for Sana Biotechnology and 9 mentions for Apogee Therapeutics. Sana Biotechnology's average media sentiment score of 0.79 beat Apogee Therapeutics' score of 0.33 indicating that Apogee Therapeutics is being referred to more favorably in the media.
79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 36.1% of Apogee Therapeutics shares are held by insiders. Comparatively, 34.9% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Apogee Therapeutics presently has a consensus price target of $73.00, suggesting a potential upside of 37.17%. Sana Biotechnology has a consensus price target of $11.67, suggesting a potential upside of 54.32%. Given Apogee Therapeutics' higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Apogee Therapeutics.
Summary
Apogee Therapeutics beats Sana Biotechnology on 9 of the 12 factors compared between the two stocks.
Get Sana Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sana Biotechnology Competitors List
Related Companies and Tools
